Comments
Loading...

Cognition Therapeutics Analyst Ratings

CGTXNASDAQ
Logo brought to you by Benzinga Data
$0.3140
0.013.87%
At close: -
$0.3027
-0.01-3.60%
After Hours: 7:13 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$14.00
Lowest Price Target1
$1.50
Consensus Price Target1
$6.25

Cognition Therapeutics Analyst Ratings and Price Targets | NASDAQ:CGTX | Benzinga

Cognition Therapeutics Inc has a consensus price target of $6.25 based on the ratings of 7 analysts. The high is $14 issued by Rodman & Renshaw on July 2, 2024. The low is $1.5 issued by B. Riley Securities on December 19, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co. on May 27, 2025, May 8, 2025, and March 24, 2025, respectively. With an average price target of $4 between HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co., there's an implied 1221.44% upside for Cognition Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Dec 24
1
Feb
2
Mar
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Chardan Capital
B. Riley Securities
Rodman & Renshaw
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Cognition Therapeutics

Buy NowGet Alert
05/27/2025Buy Now891.08%HC Wainwright & Co.
Raghuram Selvaraju20%
$5 → $3MaintainsBuyGet Alert
05/08/2025Buy Now1221.44%Chardan Capital
Daniil Gataulin52%
$8 → $4MaintainsBuyGet Alert
03/24/2025Buy Now1551.8%HC Wainwright & Co.
Raghuram Selvaraju20%
$6 → $5MaintainsBuyGet Alert
03/21/2025Buy Now2542.88%Chardan Capital
Daniil Gataulin52%
$11 → $8MaintainsBuyGet Alert
02/26/2025Buy Now3533.96%Chardan Capital
Daniil Gataulin52%
$11 → $11MaintainsBuyGet Alert
12/19/2024Buy Now395.54%B. Riley Securities
Mayank Mamtani71%
$1 → $1.5UpgradeNeutral → BuyGet Alert
12/19/2024Buy Now3533.96%Chardan Capital
Daniil Gataulin52%
$11 → $11MaintainsBuyGet Alert
12/19/2024Buy Now1882.16%HC Wainwright & Co.
Raghuram Selvaraju20%
$5 → $6MaintainsBuyGet Alert
11/27/2024Buy Now1551.8%HC Wainwright & Co.
Raghuram Selvaraju20%
$5 → $5ReiteratesBuy → BuyGet Alert
11/15/2024Buy Now3533.96%Chardan Capital
Daniil Gataulin52%
$11 → $11MaintainsBuyGet Alert
11/04/2024Buy Now1551.8%HC Wainwright & Co.
Raghuram Selvaraju20%
$5 → $5ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now3533.96%Chardan Capital
Daniil Gataulin52%
$11 → $11MaintainsBuyGet Alert
08/12/2024Buy Now1551.8%HC Wainwright & Co.
Raghuram Selvaraju20%
$7 → $5MaintainsBuyGet Alert
08/06/2024Buy Now230.36%B. Riley Securities
Mayank Mamtani71%
$5 → $1DowngradeBuy → NeutralGet Alert
08/01/2024Buy Now2212.52%HC Wainwright & Co.
Raghuram Selvaraju20%
$10 → $7MaintainsBuyGet Alert
07/30/2024Buy NowCantor Fitzgerald
Charles Duncan69%
DowngradeOverweight → NeutralGet Alert
07/02/2024Buy Now4525.04%Rodman & Renshaw
Elemer Piros27%
$14 → $14ReiteratesBuy → BuyGet Alert
06/06/2024Buy Now3533.96%Chardan Capital
Daniil Gataulin52%
→ $11Initiates → BuyGet Alert
05/29/2024Buy Now3203.6%HC Wainwright & Co.
Raghuram Selvaraju20%
→ $10Initiates → BuyGet Alert
03/28/2024Buy Now1551.8%B. Riley Securities
Mayank Mamtani71%
→ $5ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now2873.24%Oppenheimer
Jay Olson60%
$9 → $9MaintainsOutperformGet Alert
08/14/2023Buy Now1882.16%Ladenburg Thalmann
Aydin Huseynov34%
$10 → $6MaintainsBuyGet Alert
05/09/2023Buy Now2873.24%Oppenheimer
Jay Olson60%
→ $9Reiterates → OutperformGet Alert
03/24/2023Buy Now2873.24%Oppenheimer
Jay Olson60%
→ $9Reiterates → OutperformGet Alert
09/29/2022Buy Now3864.32%Cantor Fitzgerald
Charles Duncan69%
→ $12Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Cognition Therapeutics (CGTX) stock?

A

The latest price target for Cognition Therapeutics (NASDAQ:CGTX) was reported by HC Wainwright & Co. on May 27, 2025. The analyst firm set a price target for $3.00 expecting CGTX to rise to within 12 months (a possible 891.08% upside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Cognition Therapeutics (CGTX)?

A

The latest analyst rating for Cognition Therapeutics (NASDAQ:CGTX) was provided by HC Wainwright & Co., and Cognition Therapeutics maintained their buy rating.

Q

When was the last upgrade for Cognition Therapeutics (CGTX)?

A

The last upgrade for Cognition Therapeutics Inc happened on December 19, 2024 when B. Riley Securities raised their price target to $1.5. B. Riley Securities previously had a neutral for Cognition Therapeutics Inc.

Q

When was the last downgrade for Cognition Therapeutics (CGTX)?

A

The last downgrade for Cognition Therapeutics Inc happened on August 6, 2024 when B. Riley Securities changed their price target from $5 to $1 for Cognition Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Cognition Therapeutics (CGTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.

Q

Is the Analyst Rating Cognition Therapeutics (CGTX) correct?

A

While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a maintained with a price target of $5.00 to $3.00. The current price Cognition Therapeutics (CGTX) is trading at is $0.30, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch